Industry

– Neflamapimod demonstrates that it reverses the neurodegenerative process in the basal forebrain cholinergic system in animal models – – Phase 2a data in Dementia with Lewy Bodies show positive effects of neflamapimod on clinical endpoints associated with cholinergic neuronal function – – EIP Pharma plans initiation of confirmatory Phase 2b clinical trial for DLB … [Read more…]

Nearly 350 people traveled 275 miles over three days to support The Lesbian, Gay, Bisexual & Transgender Community Center’s HIV/AIDS services NEW YORK–(BUSINESS WIRE)–Today, New York City’s Lesbian, Gay, Bisexual & Transgender Community Center (“The Center”) announced that Cycle for the Cause raised over $1.6 million to sustain its HIV/AIDS prevention, education, and support services. … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “North America Travel Vaccines Market Forecast to 2028 – COVID-19 Impact and Regional Analysis By Product and Application” report has been added to ResearchAndMarkets.com’s offering. The travel vaccines market in North America is expected to grow from US$ 1,276.32 million in 2021 to US$ 2,503.59 million by 2028; it is estimated to grow … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Contract Pharmaceutical Manufacturing Market, by Service Type, by Molecule Type, and by Region – Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030” report has been added to ResearchAndMarkets.com’s offering. Pharmaceutical companies are now pushing hard to reduce overall manufacturing and research costs by outsourcing various processes related to research, development and manufacturing. … [Read more…]

Health economics study estimates significant savings for England’s NHS OXFORD, England–(BUSINESS WIRE)–#AIH–A health economic study performed by NHS England’s Oxford Academic Health Science Network (AHSN) showed that Perspectum’s LiverMultiScan – an artificial intelligence-enhanced, noninvasive liver health diagnostic tool – is a cost-effective alternative to painful, invasive liver biopsies for monitoring disease activity and treatment response … [Read more…]

LONDON–(BUSINESS WIRE)–All Seas Capital Fund I (“All Seas Capital”), a pan-European private capital fund that provides transformational capital solutions to leading founder- and entrepreneur-owned companies, announces a significant minority investment in Zimmer MedizinSysteme (“Zimmer” or the “Company”), one of the leading manufacturers of physiotherapy and aesthetics devices. A German family run business with over 50 … [Read more…]

ATLANTA–(BUSINESS WIRE)–#Biotech–Axion BioSystems today announces Maestro TrayZ, an innovative, live-cell analysis platform designed for high-throughput drug development and therapeutic discovery. The new system—featuring a slim multiplate tray design that allows for modular scalability and fits comfortably inside an incubator—joins Axion’s growing suite of next-generation Maestro products and offers a flexible, affordable option for noninvasive, label-free … [Read more…]

Positive results from Phase 2 NASH Trial (DESTINY-1) for PXL065 reported: Primary efficacy endpoint met: PXL065-treated patients achieved statistically significant improvements in the relative decrease in liver fat content at 36-weeks for all doses Paired liver biopsies confirmed strong improvement of fibrosis and other parameters PXL065 was observed to be safe and well tolerated with … [Read more…]

EINDHOVEN, the Netherlands & LAUSANNE, Switzerland & BOSTON–(BUSINESS WIRE)–ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today announced it will publish half-year 2022 financial and operating results on Tuesday, September 27, 2022. Management will host a webcast to discuss … [Read more…]

PXL065 Phase 2 trial for the treatment of NASH met its primary efficacy endpoint for liver fat content reduction at 36-weeks for all doses. Histology findings from paired liver biopsies showed strong improvement in fibrosis without worsening of NASH, consistent with dose-dependent reduction of all biomarkers related to fibrogenesis and fibrosis risk scores; improvement seen … [Read more…]